This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Vence Bonham Jr., the highest ranking official at the National Human Genome Rese...
At least 63 biopharma layoff rounds were conducted in the first quarter of this ...
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...
Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit ...
Project Optimus is changing the landscape of oncology drug development by redefi...
Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth pl...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
With the CSF-1R inhibitor space heating up, Merck Group has gone all-in on pimic...
After a year of stripping back its head count and pipeline, Carisma Therapeutics...
AIRNA, a transatlantic RNA editing biotech, is preparing to launch its lead asse...
Lundbeck has stopped development of a subcutaneous formulation of its migraine d...
It’s been an inauspicious start to the first quarter as many biotechs are forced...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
Fungi-focused biotech LifeMine Therapeutics is slimming down its staff and conso...
Christopher Corsico, M.D., has left GSK to become Sanofi’s global head of develo...
Christopher Corsico, M.D., has left GSK to become Sanofi’s global head of develo...
AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after ...
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ...
The Revolution Vibe scanner includes what the company describes as unlimited one...
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ...
Apollomics has sold the rights to its lead c-MET inhibitor in Asia, excluding Gr...
AI drug discovery firm Isomorphic Labs has completed the company’s first externa...
Earlier this month, Ian Lipkin, M.D., and his team at Columbia University submit...